Explore Our Library of Biomanufacturing Resources & Technical Data

Application Notes

rHSA Reconstitution Video Protocol

Exbumin – Reconstitution Application Note

Exbumin – Stabilizing Virus with Albumin to Improve Yield Application Note

T Cell Cryopreservation Using Exbumin®, Recombinant Human Serum Albumin, and Reduced DMSO

Blog

Albumin in Drug Delivery: Cancer’s Unexpected Achilles’ Heel

Evolving Challenges in Closed-System Biomanufacturing

How Regulatory Bodies Are Driving the Shift to Animal-Origin-Free Solutions in Cell Therapy and Vaccine Development

Innovative Solutions in Closed-System Biomanufacturing: Exploring the Tools and Technologies Driving Sterility and Efficiency

Recombinant Albumin for Stabilization of Live-Attenuated Viral Vaccines

Recombinant Virus Platforms are Out in Front in the Race to Develop Vaccines Against SARS-CoV-2 and COVID-19 Disease

SARS-CoV2 and Influenza – Double Threat

Scaling Innovation: How DiscGenics and InVitria are Leading the Future of Cell Therapy

Solving the Vaccine Supply Challenge

Why Border Disruptions Threaten Blood-Derived Raw Materials—and What Biomanufacturers Can Do About It

Why Do Some Biologics Cross the Finish Line—While Others Crash and Burn?

Catalog

InVitria Product Catalog – 2025

Data Sheets

Exbumin – Data Sheet

News

InVitria Launches Optibumin 25 rHSA

Posters

Addressing Vaccine Stability And Cold Chain Challenges With Recombinant Human Serum Albumin To Enable Global Administration

Advancing Vaccine Excellence

Exbumin®, an EMA and FDA Approved Excipient, Provides Improved Performance and Stability in Vaccine Development and Final Formulations

Virus Yield Improvement for Downstream Processing: Exbumin®, Excipient Recombinant Albumin

SDS

Exbumin – Safety Data Sheet

Use Guidelines

Exbumin – Guidelines for Use

Webinar

Accelerating Vaccine Development Through Use of Blood-Free Components

White Papers

High-Quality Recombinant Human Serum Albumin (rHSA), Exbumin™, for Improved Cell Wash Buffer Preparation

Emergence of Blood-Free Recombinant Human Albumin

Optimizing the Performance of LNP and Liposome Therapeutics with Blood-Free Recombinant Albumin